On the one hand, preclinical data suggest that alterations in the PI3K/AKT pathway shown previously may sensitize breast cancer cells to AKT inhibitors, whereas, on the other hand, a lack of correlation between PI3K/AKT pathway alterations and efficacy of AKT inhibitors seems to emerge from recent trials conducted in HR-positive breast cancer patients [36,40]. Here, AKT1 is linked to breast cancer.